Clinical implementation of the Individualized Prostate Cancer Diagnosis Pipeline

48M kr SEK

Funder	Swedish Research Council
Recipient Organization	Karolinska Institutet
Country	Sweden
Start Date	Jan 01, 2021
End Date	Dec 31, 2024
Duration	1,460 days
Number of Grantees	4
Roles	Co-Investigator; Principal Investigator
Data Source	Swedish Research Council
Grant ID	`2020-01609_VR`

Grant Description

The overall aim of this project is to further develop and implement the Individualized Prostate Cancer Diagnosis Pipeline in clinical care and significantly improve diagnostics and treatment of prostate cancer.Specific aims and hypothesesAim 1: Clinically validate and further develop the Stockholm3 test.

The hypotheses are that:Project 1: The Stockholm3 test need to be recalibrated and validated in other ethnic groups than Caucasians andProject 2: The test characteristics of the Stockholm3 test can be further improved by adding a ctDNA panelAim 2: Validate a treatment predictive biomarker profile in men with metastatic castrate resistant prostate cancer (mCRPC).

The hypothesis is that:Project 3: Treatment decisions based on biomarker profiling will significantly increase the progression free survival compared to current clinical care, translating into improved overall survival.

This hypothesis will be tested in the large multi-centre platform study ProBio, with an adaptive and randomized multi-arm biomarker driven design.